[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3112
1. Basu A, Patil N, Mohindra P, Zade B, Gujral S, Muckaden MA, Laskar S: Isolated non-Hodgkin's lymphoma of the pancreas: case report and review of literature. J Cancer Res Ther; 2007 Oct-Dec;3(4):236-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated non-Hodgkin's lymphoma of the pancreas: case report and review of literature.
  • BACKGROUND: Isolated primary pancreatic lymphoma (PPL) is a rare extra-lymphatic non-Hodgkin's lymphoma comprising less than 1% of all extra-lymphatic lymphomas.
  • It is difficult to diagnose; the vague presenting symptoms and nonspecific laboratory/radiological findings make it difficult to differentiate the condition from pancreatic adenocarcinoma.
  • Histopathological examination is of paramount importance to conclusively establish the diagnosis since the treatment involves lymphoma protocols, and prognosis and survival in PPL are considerably superior to that in adenocarcinoma pancreas.
  • DISCUSSION: A review of literature was done using a Medline search to determine the incidence and prevalence of isolated PPL and to note the diagnosis and management of previously reported cases.
  • CONCLUSION: An exceedingly rare entity, isolated PPLs need to be differentiated from pancreatic adenocarcinomas by histopathological evaluation since management is on the lines of other extralymphatic lymphomas and prognosis is significantly better.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270400.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Wong JC, Raman S: Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging; 2010 Aug;35(4):471-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resectability of pancreatic adenocarcinoma: CTA.
  • Imaging studies play an important role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Meticulous technique following a well-designed pancreas protocol is essential for maximizing the diagnostic efficacy of CT.
  • After the diagnosis of pancreatic adenocarcinoma is made, the key to management is staging to determine resectability.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Nov;213(2):468-72 [10551228.001]
  • [Cites] Radiology. 2009 Mar;250(3):758-65 [19164113.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] J Comput Assist Tomogr. 2001 May-Jun;25(3):337-42 [11351180.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]
  • [Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):626-33 [12086901.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1217-24 [12704026.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):202-6 [8661548.001]
  • [Cites] AJR Am J Roentgenol. 1997 Apr;168(4):971-7 [9124153.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Radiology. 1999 Jan;210(1):71-4 [9885589.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10):753-63 [15545675.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64 [16549332.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] AJR Am J Roentgenol. 2007 Nov;189(5):1044-50 [17954638.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1653-66 [18025509.001]
  • [Cites] Radiology. 2007 Dec;245(3):770-8 [17951353.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):111-25 [18272835.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1509-12 [10584793.001]
  • (PMID = 19468791.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2900587
  •  go-up   go-down


3. Reddy SK, Tyler DS, Pappas TN, Clary BM: Extended resection for pancreatic adenocarcinoma. Oncologist; 2007 Jun;12(6):654-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended resection for pancreatic adenocarcinoma.
  • Adenocarcinoma of the pancreas presents a number of therapeutic challenges.
  • TP should not be performed for most cases of adenocarcinoma of the pancreatic head because of the nominal incidence of lymph node involvement along the body and tail of the pancreas, the scarcity of multicentric disease, and the better management of pancreatic leaks after PD.
  • The disappointing experience with extended resections underscores the need for better adjuvant systemic strategies and the interdisciplinary care of patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602057.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


Advertisement
4. Lequaglie C, Della Morte A, Feudale E, Giudice G: [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma]. Chir Ital; 2007 Nov-Dec;59(6):901-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma].
  • [Transliterated title] Metastasi umica metacrona dello sterno da adenocarcinoma del pancreas.
  • Sternal metastases from adenocarcinoma of the pancreas are extremely rare, and even more so when solitary.
  • Two years earlier, the patient reported on here, a 67-year-old man with a solitary osteolytic lesion of the sternal manubrium, had undergone a duodeno-cephalopancreatectomy for adenocarcinoma of the pancreas (G2, pY3, pN1) followed by adjuvant radio-chemotherapy.
  • The histological examination revealed secondary adenocarcinoma with 3 mediastinal metastatic lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Pancreatic Neoplasms. Sternum

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361001.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Ausania F, Caricato M, Borzomati D, Giarratano G, Garberini A, Rosignoli A, Ripetti V, Tonini G, Coppola R: [Cerebellar metastasis from pancreatic adenocarcinoma: report of a clinical case]. Suppl Tumori; 2005 May-Jun;4(3):S62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebellar metastasis from pancreatic adenocarcinoma: report of a clinical case].
  • [Transliterated title] Metastasi cerebellare da adenocarcinoma del pancreas descrizione di un caso clinico.
  • We describe a case of a metacronous cerebellar metastasis from pancreatic adenocarcinoma occurred in a 67 years old male.
  • Central nervous system metastases from pancreatic carcinoma are mostly autoptic findings.
  • To our knowledge, this is the first case reported in literature of cerebellar metastasis from pancreatic cancer; furthermore, this case calls attention on vomit presentation that could be erroneously attributed to an abdominal relapse.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437906.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. D'Onofrio M, Vecchiato F, Gallotti A, Falconi M, Capelli P, Pozzi Mucelli R: Small undifferentiated pancreatic adenocarcinoma which mimics IPMN at imaging. JOP; 2009;10(4):406-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small undifferentiated pancreatic adenocarcinoma which mimics IPMN at imaging.
  • CONTEXT: To present the case of an unusual presentation at imaging of a very small solid undifferentiated pancreatic adenocarcinoma which mimics a side-branch intraductal papillary mucinous neoplasm.
  • CASE REPORT: The patient came to our hospital for a revaluation of a cystic pancreatic lesion.
  • A small cystic lesion of about 1.5 cm in diameter was seen in the posterior aspect of the pancreatic uncinate process A very small, solid, vascularized nodule was detected at CEUS within the lesion.
  • MRI confirmed the presence of an intralesional nodule and communication with the main pancreatic duct was demonstrated, suggesting the diagnosis of intraductal papillary mucinous neoplasm with solid intralesional tissue.
  • An undifferentiated adenocarcinoma having a notable peripheral inflammatory reaction and dilated branch duct was finally diagnosed.
  • CONCLUSION: To our knowledge, we present for the first time, the case of a very small solid undifferentiated pancreatic adenocarcinoma of the uncinate process which mimicked a side-branch intraductal papillary mucinous neoplasm at imaging.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581744.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Jin G, Hu XG, Ying K, Tang Y, Liu R, Zhang YJ, Jing ZP, Xie Y, Mao YM: Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays. World J Gastroenterol; 2005 Nov 7;11(41):6543-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays.
  • AIM: To study the pathogenetic processes and the role of gene expression by microarray analyses in expediting our understanding of the molecular pathophysiology of pancreatic adenocarcinoma, and to identify the novel cancer-associated genes.
  • METHODS: Nine histologically defined pancreatic head adenocarcinoma specimens associated with clinical data were studied.
  • In pancreatic adenocarcinoma tissue, several invasion and metastasis related genes showed their high expression levels, suggesting that poor prognosis of pancreatic adenocarcinoma might have a solid molecular biological basis.
  • CONCLUSION: The application of cDNA microarray technique for analysis of gene expression patterns is a powerful strategy to identify novel cancer-associated genes, and to rapidly explore their role in clinical pancreatic adenocarcinoma.
  • Microarray profiles provide us new insights into the carcinogenesis and invasive process of pancreatic adenocarcinoma.
  • Our results suggest that a highly organized and structured process of tumor invasion exists in the pancreas.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425432.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4355802
  •  go-up   go-down


8. Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, Schulick RD, Pawlik TM: Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer; 2007 Dec 1;110(11):2484-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?
  • Specifically, the role of hepatic resection for metastatic periampullary or pancreatic adenocarcinoma remains controversial.
  • METHODS: Between 1995 and 2005, 1563 patients underwent surgical resection for periampullary carcinoma (n=608 patients) or pancreatic adenocarcinoma (head, n=905 patients; tail, n=50 patients).
  • RESULTS: Of the 1563 patients who underwent resection of periampullary or pancreatic adenocarcinoma, 22 patients (1.4%) underwent simultaneous hepatic resection for synchronous liver metastasis.
  • The primary tumor site was ampullary (n=1 patient ), duodenal (n=2 patients), distal bile duct (n=2 patients), or pancreas (head, n=10 patients; tail, n=7 patients).
  • Pancreatic (median, 5.9 months) versus nonpancreatic (median, 9.9 months) primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous liver metastasis (P=.43).
  • CONCLUSIONS: Even in well selected patients with low-volume metastatic liver disease, simultaneous resection of periampullary or pancreatic carcinoma with synchronous liver metastases did not result in long-term survival in the overwhelming majority of patients.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17941009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Barreda Bolaños F, Landeo Aliaga I, Pando Huarcaya S, Bayro Peñaloza F: [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography]. Rev Gastroenterol Peru; 2008 Apr-Jun;28(2):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography].
  • [Transliterated title] Adenocarcinoma de páncreas en paciente joven diagnosticado por ultrasonografía endoscópica.
  • The Pancreatic adenocarcinoma appears generally in patients with more than 60 years old.
  • The tomografic image showed a mass located in the head of the pancreas with hepatic and ganglionar metastases.
  • It was evaluated by means of endoscopic ultrasonography (USE) and performed a directed fine needle puncture aspiration (PAAF), that obtained a bad differentiated adenocarcinoma from the pancreas.
  • We present the case by the unusual occurrence in the related age group and by the importance of the puncture guided by endoscopic ultrasonography in the diagnosis and handling of this pathology [corrected]
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):293
  • (PMID = 18641779.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


10. Badía Bartolomé C, Díaz Formoso FJ, Rodríguez Falcón R, Marchena Gómez J: [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma]. Gastroenterol Hepatol; 2009 Jan;32(1):22-8
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma].
  • [Transliterated title] Pancreatitis del surco y su diagnóstico diferencial con el adenocarcinoma de páncreas.
  • We analyzed the clinical, radiographic and histologic characteristics, as well as the difficulties that arose in the differential diagnosis between groove pancreatitis (a benign entity consisting of a segmental form of chronic pancreatitis occurring as a sheet-like scar in the area of pancreatoduodenal groove) and adenocarcinoma of the pancreas.
  • To this end, four cases with abnormalities in the groove area were retrospectively reviewed, three with groove pancreatitis, and one with adenocarcinoma of the pancreas.
  • The important role of imaging techniques is highlighted, with emphasis on magnetic resonance imaging of the pancreas and magnetic resonance cholangiography, which reveal certain differentiating characteristics between these two entities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Duodenitis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Cholelithiasis / complications. Cholelithiasis / diagnosis. Chronic Disease. Diagnosis, Differential. Duodenum / pathology. Fatal Outcome. Humans. Intestinal Mucosa / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreaticoduodenectomy. Pancreatitis, Alcoholic / complications. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Hepatol. 2009 Nov;32(9):662-3 [19525034.001]
  • (PMID = 19174095.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


11. Fabregat J, Busquets J, Peláez N, Jorba R, García-Borobia F, Masuet C, Valls C, Ruiz-Osuna S, Serrano T, Galán M, Cambray M, Laquente B, Ramos E, Rafecas A: [Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases]. Cir Esp; 2010 Dec;88(6):374-82
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases].
  • [Transliterated title] Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos.
  • INTRODUCTION: Surgery is the accepted treatment in adenocarcinoma of the head of the pancreas; however, the long-term survival continues to be low.
  • The aim of this study is to define prognostic factors of long-term survival after cephalic duodenopancreatectomy due to pancreatic adenocarcinoma.
  • MATERIAL AND METHODS: We have collected data on the treatment of adenocarcinoma of the head of the pancreas (ADHP) by means of a cephalic duodenopancreatectomy (CDP) performed n the Bellvitge University Hospital (Barcelona) from 1991 to 2007.
  • CONCLUSIONS: Surgery of head of the pancreas adenocarcinoma must include an adequate lymphadectomy, and must be performed with a low morbidity and without the need of a peri-operative transfusion.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AEC. Published by Elsevier Espana. All rights reserved.
  • [CommentIn] Cir Esp. 2011 Jun-Jul;89(6):411; author reply 412 [21550599.001]
  • (PMID = 21030012.001).
  • [ISSN] 1578-147X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Khosravi Shahi P, Díaz Muñoz de la Espada VM: [Pancreatic adenocarcinoma: therapeutical update]. An Med Interna; 2005 Aug;22(8):390-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma: therapeutical update].
  • [Transliterated title] Adenocarcinoma de páncreas: actualizaciones terapéuticas.
  • Cancer of the exocrine pancreas continues to be a major unsolved health problem.
  • Because of difficulties in diagnosis, the aggressiveness of pancreatic cancers, and the lack of effective systemic therapies, generally fewer than 5% of patients with adenocarcinoma of the pancreas survive 5 years after diagnosis.
  • The median survival in metastatic pancreatic cancer is nearly six months.Today, surgery remains the only curative therapeutic option, and the standard treatment in patients with advanced disease is gemcitabine.
  • New strategies for resectable and unresectable pancreatic cancer are under active investigation,such as neoadjuvant or adjuvant chemoradiotherapy or combinations of gemcitabine with new cytotoxic agents (oxaliplatin, cetuximab, gefitinib, bevacizumab) with promising results.
  • In patients with locally advanced pancreatic cancer and good performance status, chemoradiotherapy should be considered.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351494.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 37
  •  go-up   go-down


13. Busquets J, Fabregat J, Jorba R, Peláez N, García-Borobia F, Masuet C, Valls C, Martínez-Carnicero L, Lladó L, Torras J: [Surgical treatment of pancreatic adenocarcinoma by cephalic duodenopancreatectomy (Part 1). Post-surgical complications in 204 cases in a reference hospital]. Cir Esp; 2010 Nov;88(5):299-307
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic adenocarcinoma by cephalic duodenopancreatectomy (Part 1). Post-surgical complications in 204 cases in a reference hospital].
  • [Transliterated title] Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (Parte 1). Complicaciones postoperatorias en 204 casos en un centro de referencia.
  • INTRODUCTION: Cephalic duodenopancreatectomy (CDP) is the treatment of choice in cancer of the head of the pancreas.
  • The aim of this article is to define variables that influence post-surgical morbidity and mortality after cephalic duodenopancreatectomy due to pancreatic adenocarcinoma (PA) cancer of the head of the pancreas (CHP).
  • Post-surgical complications were detected in 45% of cases, the most frequent being: slow gastric emptying (20%), surgical wound infection (17%), pancreatic fistula (10%), and serious medical complications (8%).
  • Pancreatic fistula was not a factor associated with post-surgical mortality.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenum / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AEC. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20663494.001).
  • [ISSN] 1578-147X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Lowery M, O'Reilly EM: Targeted therapies for pancreatic adenocarcinoma. Minerva Chir; 2009 Oct;64(5):501-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for pancreatic adenocarcinoma.
  • The majority of patients diagnosed with adenocarcinoma of the pancreas have advanced disease at presentation, with only 20% surviving beyond one year.
  • Systemic therapy for pancreatic adenocarcinoma to date has failed to provide more than a very modest survival benefit for patients with advanced disease.
  • However, the past decade has seen significant advances in the understanding of the molecular pathogenesis of pancreatic cancer, culminating in the sequencing of the pancreatic cancer genome.
  • New generations of therapeutic agents targeting key oncogenic cellular signaling pathways are currently under evaluation in advanced pancreatic adenocarcinoma.
  • Herein the authors review the evidence to date for the use of novel cytotoxic and molecularly targeted agents in pancreatic adenocarcinoma, and discuss key areas for future therapeutic development.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. ras Proteins / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859040.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.2 / src-Family Kinases; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 127
  •  go-up   go-down


15. Ioka T, Takakura R, Nakaizumi A, Tanaka S, Iishi H, Nakamura S, Nishiyama K, Oohigashi H, Ishikawa O, Watanabe A, Mukai S: A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma.
  • : e15512 Background: Some of locally advanced pancreatic cancers (LAPC) are considered to include a potential micro metastasis.
  • METHODS: Patients with histologically or cytologically proven pancreatic adenocarcinoma were eligible for this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ueno H, Okusaka T, Furuse J, Ishii H, Saijo N, Saito Y, Sawada J, Sakamoto H, Yoshida T, Sato Y: Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy.
  • We performed a genome-wide association study (GWAS) in Japanese patients with stage IV pancreatic adenocarcinoma receiving gemcitabine (Gem) monotherapy.
  • METHODS: Metastatic pancreatic ductal adenocarcinoma patients who had previously received neither radiation nor chemotherapy were eligible in this study.
  • CONCLUSIONS: GWAS is a powerful tool to search for new prognostic biomarkers for patients with stage IV pancreatic adenocarcinoma receiving Gem monotherapy and may reveal as yet unexplored molecular pathways which correlate with drug response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964191.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Marten A, Büchler MW, Wente MN, Schmidt J: Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology. J Clin Oncol; 2009 May 20;27(15_suppl):4626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology.
  • : 4626 Background: Pancreatic adenocarcinoma as an aggressive tumor still lacks specific markers.
  • Resection offers the only potential cure, and earlier diagnosis could benefit many patients.
  • Complement regulatory proteins are highly expressed on pancreatic carcinoma cells and detectable in patient's urine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964206.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Cohen DJ, Ryan T, Moskovits T, Cazeau N, Newman E, Pachter HL, Hochster HS: Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer.
  • : e15594 Background: The addition of E to G results in improved survival for patients(pts) with locally advanced and metastatic pancreatic cancer.
  • Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF.
  • Sorafenib, a multitargeted tyrosine kinase inhibitor which targets VEGR 1-3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize with these agents resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression and therefore improve outcome.
  • METHODS: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, ECOG PS 0-1, and adequate organ function were eligible and received G 1,000 mg/m<sup>2</sup> over 30 min weekly × 3 every 4 weeks.
  • CONCLUSIONS: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to gemcitabine alone, except for very manageable cutaneous reactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol; 2009 May 20;27(15_suppl):4532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.
  • : 4532 Background: The EGFR inhibitor, erlotinib (E), in combination with gemcitabine (G), provides a significant survival benefit in metastatic pancreatic cancer.
  • METHODS: Chemo-naïve patients (pts) with metastatic pancreatic adenocarcinoma and KPS of 60-100 were randomized to GE-placebo (GE-P) or GE-B; pts received B/P 5mg/kg q2w plus E (100mg/d) and G (1,000mg/m<sup><sup>2</sup></sup>) given weekly for 7 weeks during the first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles.
  • JCO 2007), in pts with advanced pancreatic cancer.
  • Studies are under way to prospectively investigate the relationship between rash and efficacy with erlotinib-based regimens in pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Reni M, Cereda S, Aprile G, Tronconi MC, Milandri C, Passoni P, Rognone A, Balzano G, Di Carlo V, Villa E: A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer.
  • : 4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hwang JY, Yoo C, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S, Lee J: A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy.
  • : 4618 Background: Only few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy.
  • We conducted a randomized phase II trial of modified FOLFOX vs. modified FOLFIRI.3 as second-line regimen for the patients with gemcitabine refractory pancreatic cancer ( NCT00786006 ).
  • METHODS: Patients with advanced pancreatic adenocarcinoma previously treated with gemcitabine were randomly assigned to FOLFOX or FOLFIRI.3 stratifying by age (≤ 65 vs. >65), performance status (0-1 vs. 2) and prior response to gemcitabine (PR/SD vs. PD).
  • CONCLUSIONS: Both FOLFOX and FOLFIRI.3 were tolerated with manageable toxicity, offering modest activity as second-line treatment of patients with advanced or metastatic pancreatic cancer, previously treated with gemcitabine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ho AS, Huang X, Cao H, Koong AC, Le QT: Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):4624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.
  • Moreover, since pancreatic adenocarcinomas have been previously shown to be extremely hypoxic, we hypothesized that miR-210 may be elevated in the plasma of these patients compared to non-cancer controls.
  • Here, we compared the circulating plasma levels of miR-210 in pancreatic cancer patients and controls using a novel miRNA extraction approach and quantitative PCR.
  • METHODS: Pretreatment EDTA plasma samples were obtained from pancreatic cancer patients and age-matched non-cancer controls. miRNA was extracted from 40ul of plasma and reverse transcribed to cDNA.
  • The procedure was performed on the initial 11 pairs of age-matched pancreatic cancer patients and non- cancer controls, then validated with a second cohort of 12 pancreatic cancer patients and 11 controls.
  • There is a statistically significant four-fold increase of mir-210 expression in pancreatic cancer patients compared to normal controls (Student's t-test, p <0.0001).
  • Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964211.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bonnetain F, Maillard E, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Dahan L: Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e17544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Dahan L, Methy N, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Bonnetain F: Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Maréchal R, Demetter P, Berton A, Salmon I, Van Laethem J: Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT).
  • This chemoreceptor could be implicated in the resistance of pancreatic cancer cells to RCT and its targeted inhibition deserves clinical evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Oh D, Lee K, Lee K, Sohn C, Park Y, Zang D, Ryoo H, Bang Y: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol; 2009 May 20;27(15_suppl):4607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research.
  • : 4607 Background: To confirm the efficacy and toxicity of erlotinib (E) in combination with gemcitabine (G) and capecitabine (C) when used as a first-line therapy in patients (pts) with metastatic/recurrent pancreatic cancer Methods: Pts with advanced pancreatic adenocarcinoma, with measurable lesion were eligible for the study.
  • Locally advanced pancreatic cancer was excluded.
  • CONCLUSIONS: Erlotinib in combination with gemcitabine and capecitabine showed promising efficacy and good tolerability in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J, Hidalgo M: SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):4525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.
  • : 4525 Background: Pancreatic cancer cells and surrounding stroma are known to overexpress SPARC (secreted protein acid rich in cysteine), which is associated with poor clinical outcomes. nab-P, an albumin-bound nanoparticle form of paclitaxel increased tumor accumulation of paclitaxel through binding of albumin to SPARC.
  • METHODS: nab-P doses (100-150 mg/m<sup>2</sup>) + (G) (1000 mg/m<sup>2</sup>) were given on days 1, 8, and 15 of a 28-day cycle to pts with metastatic pancreatic adenocarcinoma and with no prior chemotherapy for their metastatic disease.
  • CONCLUSIONS: The combination of nab-P and G was generally well tolerated and had substantial enough antitumor activity in patients with pancreatic cancer to warrant a phase III clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Thieltges S, Kalinina T, Krohn A, Simon R, Moeller-Krull M, Dierlamm J, Izbicki J, Yekebas E: Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods. J Clin Oncol; 2009 May 20;27(15_suppl):e15609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods.
  • : e15609 Background: Pancreatic adenocarcinoma is a genetically highly complex and heterogenous tumor type with strong genetic instability which makes it resistant to therapy.
  • METHODS: We report the use of an Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 (906,600 SNPs) to screen for gene copy number changes and allelic imbalances in 8 microdissected primary pancreatic tumors and 7 established pancreatic cancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • : e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Patient characteristics were: median age; 67.5 (45-80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.
  • AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.
  • CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • 6 pts underwent secondary pancreatic resection (4 compete resection and 1 pt with histological complete remission).
  • CONCLUSIONS: The association docetaxel+cisplatin+radiotherapy has limited effect in patients with locally advanced pancreatic carcinoma but major objective responses have been observed allowing secondary resections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.
  • : 4602 Background: Current treatments of non-metastatic, unresectable pancreatic cancer result in poor survival and nearly uniform local persistence of disease.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • GTV was defined on pancreas protocol CT in the treatment position.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Brown D, Boyd A, Henrickson C, Hampton J, Almani F, Ben-Josef E, Zalupski M, Simeone D, Taylor J, Armitage R, Riba M: Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas. J Clin Oncol; 2009 May 20;27(15_suppl):e15678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas.
  • : e15678 Purpose: To evaluate the prevalence of depression, sleep related disturbances and anxiety and their effect on quality of life in patients with recently diagnosed adenocarcinoma of the pancreas who present to a multidisciplinary pancreatic cancer clinic.
  • A minority (2 pts, 8%) had PSWQ scores characteristic of an anxiety disorder, while 33% (8 pts) had moderate anxiety scores.
  • CONCLUSIONS: Our results indicate that mild to moderate depressive symptoms, anxiety and potential sleep problems are common in patients referred to a multidisciplinary pancreatic cancer clinic.
  • To better characterize the relationship of depression (and potential causes) with pancreatic cancer, additional prospective longitudinal studies are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, Nicoletti R, Zerbi A, Villa E, Reni M: A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):4614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel.
  • : 4614 Background: The combination of cisplatin (P), epirubicin (E), 5-fluorouracil (F) and gemcitabine (G) (PEFG regimen) yielded a progression-free survival at 6 months from treatment start (PFS6) of about 50% and a 1-year overall survival (OS) around 40% in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).
  • CONCLUSIONS: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Smith CD, Maines LW, Zhuang Y, Green CL, Keller SN, Beljanski V, Knaak C, Wang W: Preclinical development of orally available sphingosine kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):e14615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity was assessed in an allogeneic model utilizing murine JC mammary adenocarcinoma cells growing in Balb/c mice, and a xenograft model of human Bxpc pancreatic adenocarcinoma cells growing in scid-mice.
  • CONCLUSIONS: These newly developed SK inhibitors provide orally-available drug candidates for the treatment of pancreatic cancer and other diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Mazzer M, Zanon E, Foltran L, De Pauli F, Cardellino G, Iaiza E, Ermacora P, Aprile G, Fasola G: Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15597

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma.
  • : e15597 Background: Few regimens showed efficacy in advanced pancreatic cancer patients (pts) who had failed a first-line gemcitabine-based therapy.
  • METHODS: Pancreatic cancer pts with advanced disease, PS>60, age>18 years, who progressed after a gemcitabine-based therapy were enrolled in a phase II trial, and treated with pemetrexed 500 mg/mq followed by oxaliplatin 120 mg/mq, day 1 every 3 weeks, together with adequate oral folinic acid and intramuscular vitamin B12 supplementation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lee J, Lee S, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S: Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA).
  • : e15553 Background: To determine the efficacy and safety of fixed dose rate (FDR) gemcitabine and capecitaibne (GX) combination chemotherapy for locally advanced pancreatic adenocarcinoma Methods: Patients with histologically confirmed LAPA were eligible for this prospective phase II trial.
  • Dynamic pancreas/pelvic CT, MRI and FDG-PET were undertaken to assess the resectability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Moore MJ, Tang P, Renouf D, Major P, Hedley D, Paterson V, Wang L, Dhesy-Thind B, Southwood B, Doyle L: A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer.
  • Preclinical studies suggest that Eribulin may be effective in pancreatic cancer.
  • The primary objective of this study was to determine the objective response rate (complete and partial) to Eribulin in patients with advanced, pancreatic adenocarcinoma that had progressed after gemcitabine based therapy.
  • METHODS: Eligibility criteria included histologically confirmed pancreatic adenocarcinoma; measurable locally advanced, or metastatic disease; disease progression after gemcitabine; and ECOG performance status 0-2.
  • CONCLUSIONS: Eribulin was well tolerated and did not result in any objective responses in refractory pancreatic cancer.
  • Further studies of eribulin in pancreatic cancer may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Carr BI, Summers D, Menefee L, Pierpoint S, Yeo C, Kennedy E, Lavu H: Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis.
  • : e20692 Background: In order to begin to understand the effects of disease on the patient (pt) and possibly of the pt on the disease, we have begun a systematic psychological inventory of all our pts who have has a pancreatectomy for pancreas adenocarcinoma and have began to correlate this with disease extent, and later with survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961756.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Balachandran A, Darden DL, Tamm EP, Faria SC, Evans DB, Charnsangavej C: Arterial variants in pancreatic adenocarcinoma. Abdom Imaging; 2008 Mar-Apr;33(2):214-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial variants in pancreatic adenocarcinoma.
  • Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma.
  • Unexpected variant arterial anatomy or tumor involvement of aberrant arteries may complicate pancreatic surgery.
  • We describe here the arterial variant anatomy of the pancreas and its identification by multidetector CT imaging, with and without the aid of post-processed volume-rendered images.
  • [MeSH-major] Adenocarcinoma / blood supply. Celiac Artery / abnormalities. Mesenteric Arteries / abnormalities. Pancreas / blood supply. Pancreatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17435979.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 22
  •  go-up   go-down


45. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1301-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of pancreatic adenocarcinoma by imaging studies.
  • Imaging studies play a crucial role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with pancreatic adenocarcinoma.
  • To maximize the diagnostic efficacy of CT, use of a pancreas protocol is mandatory.
  • The sensitivity of CT for diagnosis of pancreatic adenocarcinoma (89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.
  • Magnetic resonance imaging has not been shown to perform better than CT for the diagnosis and staging of pancreatic adenocarcinoma, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.
  • Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for diagnosis and staging of patients with pancreatic adenocarcinoma is limited.
  • Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with pancreatic adenocarcinoma, but its utility has not been established.
  • Endoscopic ultrasound is generally considered superior to CT for the diagnosis and local staging of pancreatic cancer, but is limited by availability and inability to assess for distant metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreas / radiography. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948228.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


46. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR: Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology; 2005 Nov;129(5):1454-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Markers to differentiate among pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas would be of significant clinical utility.
  • This study was therefore designed to analyze the proteome of such specimens and identify new candidate proteins for differential diagnosis.
  • METHODS: A PowerBlot analysis with more than 900 well-characterized antibodies was performed with tissue specimens from patients with chronic pancreatitis, pancreatic adenocarcinoma, and normal pancreas.
  • RESULTS: A total of 30 and 102 proteins showed significant deregulation between normal pancreas when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a substantial proportion were found similarly dysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identified as potential disease-specific markers.
  • CONCLUSIONS: A large number of proteins are differentially expressed in chronic pancreatitis and pancreatic adenocarcinoma compared with normal pancreas.
  • [MeSH-major] Adenocarcinoma / physiopathology. Pancreatic Neoplasms / physiopathology. Pancreatitis, Chronic / physiopathology. Protein Array Analysis. Proteomics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285947.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Misek DE, Kuick R, Hanash SM, Logsdon CD: Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma. Methods Mol Med; 2005;103:175-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma.
  • In this chapter we describe our approach to the profiling of pancreatic adenocarcinoma to illustrate the various steps and methods involved in this type of study.
  • Pancreatic adenocarcinoma is a particularly challenging subject for gene profiling, as these tumors have a profound desmoplastic response such that neoplastic epithelium makes up only a small proportion of the tissue mass.
  • We have utilized statistical comparisons of gene expression between adenocarcinoma, normal pancreas, samples of chronic pancreatitis, and pancreatic cancer cell lines that provides a means to deduct the influence of the stromal elements.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542906.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides
  •  go-up   go-down


48. Miller FH, Rini NJ, Keppke AL: MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol; 2006 Oct;187(4):W365-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of adenocarcinoma of the pancreas.
  • OBJECTIVE: CT is the established imaging technique for evaluation of pancreatic adenocarcinoma.
  • The objective of this study is to illustrate the strengths of MRI for evaluating pancreatic adenocarcinoma.
  • CONCLUSION: The superior soft-tissue contrast of MRI compared with CT is useful in the detection and characterization of non-contour-deforming pancreatic masses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / radiography. Diagnosis, Differential. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Pancreatitis / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985107.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC: Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer; 2010 Jul 27;103(3):391-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
  • BACKGROUND AND AIMS: The serum/plasma proteome was explored for biomarkers to improve the diagnostic ability of CA19-9 in pancreatic adenocarcinoma (PC).
  • [MeSH-major] Adenocarcinoma / blood. Apolipoprotein A-I / blood. Apolipoprotein C-I / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoma, Pancreatic Ductal / blood. Proteomics / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3512-20 [18781364.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2880-4 [18803289.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] World J Surg. 2009 Apr;33(4):716-22 [19082654.001]
  • [Cites] J Mol Biol. 2009 Apr 3;387(3):628-38 [19236880.001]
  • [Cites] Eur J Surg Oncol. 2009 Jun;35(6):605-10 [19128923.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8 [19433314.001]
  • [Cites] Clin Chem Lab Med. 2009;47(6):713-23 [19426140.001]
  • [Cites] Metabolism. 2009 Aug;58(8):1131-6 [19493551.001]
  • [Cites] Clin Sci (Lond). 2010 Jan;118(1):79-85 [19456294.001]
  • [Cites] Clin Chem Lab Med. 2009;47(11):1389-94 [19817643.001]
  • [Cites] Cancer Sci. 2009 Dec;100(12):2292-301 [19775290.001]
  • [Cites] Med Sci Monit. 2000 Mar-Apr;6(2):325-9 [11208331.001]
  • [Cites] J Lipid Res. 2001 Nov;42(11):1727-39 [11714842.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6 [11983868.001]
  • [Cites] Electrophoresis. 2002 Sep;23(17):3048-61 [12207315.001]
  • [Cites] Proteomics. 2003 Mar;3(3):243-8 [12627376.001]
  • [Cites] Ann Emerg Med. 2003 Aug;42(2):292-7 [12883521.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Feb;19(2):182-6 [14731128.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):860-8 [14871961.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2397-405 [15059891.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Biochim Biophys Acta. 1995 Jul 13;1257(2):174-80 [7619858.001]
  • [Cites] J Lipid Res. 1999 Mar;40(3):543-55 [10064743.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):674-86 [15548376.001]
  • [Cites] Biochemistry. 2005 Jan 18;44(2):471-9 [15641771.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1073-85 [15709174.001]
  • [Cites] Oncology. 2005;68(1):79-86 [15864000.001]
  • [Cites] Electrophoresis. 2005 Jul;26(14):2823-34 [15934056.001]
  • [Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):302-7 [15876873.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10613-22 [16288055.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):981-9 [16186794.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1670-8 [16697731.001]
  • [Cites] Pancreas. 2007 Mar;34(2):205-14 [17312459.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2810-22 [18037960.001]
  • (PMID = 20588270.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Apolipoprotein C-I; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Protein Isoforms; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2920018
  •  go-up   go-down


50. Bateman AC, Judd M, Radenkovic D, Johnson CD: CD117/KIT expression in pancreatic adenocarcinoma. Pancreas; 2008 Jan;36(1):76-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD117/KIT expression in pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma has a poor prognosis, and therefore, targeted molecular therapy may be beneficial.
  • Marked differences in the incidence of CD117/KIT expression have been reported in pancreatic adenocarcinoma.
  • The aim of this study was to test the hypothesis that CD117/KIT expression is unusual in pancreatic adenocarcinoma.
  • METHODS: CD117/KIT immunohistochemistry was performed on 23 archival pancreatic adenocarcinoma samples using 2 primary antibodies.
  • However, CD117/KIT expression was also identified using the latter within nuclei and benign pancreatic epithelium, suggesting that artifactual staining was occurring.
  • CONCLUSIONS: Pancreatic adenocarcinoma does not express CD117/KIT as assessed using the primary immunohistochemical antibody usually used in our laboratory for CD117/KIT detection.
  • The variation in reported incidence of CD117/KIT expression in pancreatic adenocarcinoma is because of methodological differences in immunohistochemical technique.
  • [MeSH-major] Adenocarcinoma / chemistry. Pancreatic Neoplasms / chemistry. Proto-Oncogene Proteins c-kit / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192885.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


51. Dariusz Szajda S, Waszkiewicz N, Stypułkowska A, Dadan J, Zwierz K: Lysosomal exoglycosidases in serum and urine of patients with pancreatic adenocarcinoma. Folia Histochem Cytobiol; 2010 Sep 30;48(3):351-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysosomal exoglycosidases in serum and urine of patients with pancreatic adenocarcinoma.
  • The aim of the present paper was evaluation the activity of HEX, GAL, FUC and MAN in serum and urine of patients with pancreatic adenocarcinoma.
  • Serum and urine samples were collected from 15 patients with adenocarcinoma of the pancreas and 15 healthy persons.
  • The activity of lysosomal exoglycosidases was determined by the method of Marciniak et al. adapted to serum and urine of patients with adenocarcinoma of the pancreas.
  • Our results indicate significant decrease in activity of GAL (p=0.037) in serum of patients with pancreatic adenocarcinoma, significant increase in activity of HEX (p<0.001) and FUC (p=0.027) in serum, and HEX (p=0.003) in urine, as well as significant decrease of FUC (p=0.016) and MAN (p=0.029) in urine o patients with adenocarcinoma of the pancreas, in comparison to the control group.
  • Increase in activity of some lysosomal enzymes in serum and urine of pancreatic adenocarcinoma patients, may indicate on destruction of pancreatic tissue by pancreatic adenocarcinoma.
  • Determination of the HEX, GAL, FUC and MAN in serum and urine may be useful in diagnostics of pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21071338.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Glycoconjugates; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.23 / beta-Galactosidase; EC 3.2.1.24 / alpha-Mannosidase; EC 3.2.1.51 / alpha-L-Fucosidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


52. Stipa F, Alessandroni L, Cimitan A, Burza A, Cavallotti C, Cavallini M, Tersigni R, Ziparo V: [Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head and papilla of Vater]. Minerva Chir; 2009 Aug;64(4):395-406
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head and papilla of Vater].
  • [Transliterated title] Duodenocefalopancreatectomia per adenocarcinoma della testa del pancreas e della papilla di Vater.
  • AIM: The authors report their consecutive experience in the surgical management of adenocarcinoma (ADC) of head of pancreas and papilla of Vater, in order to review the available literature.
  • METHODS: One hundred and seventy cases (131 in the head of pancreas and 39 in the papilla of Vater) were operated upon for ADC by radical pancreaticoduodenectomy in the period 1972-2005.
  • RESULTS: Postoperative morbidity was reported in 66 patients (38.8%) and pancreatic fistulae were observed in 39 patients (22.9%).
  • Five-year survival for pancreatic ADC was 75% in stage IA, 43.9% in stage IB and IIA, 3.2% in stage IIB.
  • The Wirsung duct has to be anastomosed directly to the jejunum and the pancreatic section needs to be checked.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648859.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 79
  •  go-up   go-down


53. Clark CE, Beatty GL, Vonderheide RH: Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett; 2009 Jun 28;279(1):1-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.
  • This is an especially important issue in pancreatic cancer, which although inflammatory in vivo is nevertheless highly aggressive and nearly always lethal.
  • Here, we review emerging data obtained from novel genetically defined mouse models of pancreatic adenocarcinoma that suggest that the immune system may be complicit in the inception and progression of pancreatic cancer.
  • Host immune cells with suppressive properties infiltrate the pancreas early during tumorigenesis, even at the earliest stages of neoplasia, preceding and effectively undermining any lymphocytes with potential antitumor function.
  • Thus, in pancreatic adenocarcinoma, the failure of immunosurveillance is likely an early event during tumorigenesis, a concept that carries important implications for the design of novel immunotherapeutics in this disease.
  • [MeSH-major] Adenocarcinoma / immunology. Neoplasms, Experimental / immunology. Pancreatic Neoplasms / immunology. Tumor Escape

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013709.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Number-of-references] 70
  •  go-up   go-down


54. Hucl T, Kylanpää-Bäck ML, Witt H, Künzli B, Lempinen M, Schneider A, Kemppainen E, Löhr M, Friess H, Ockenga J, Rosendahl J, Schulz HU, Gress T, Singer MV, Pfützer RH: HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med; 2007 Jul;9(7):479-83
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma.
  • PURPOSE: The homozygous p.C282Y variant of the HFE gene is a major risk factor for hereditary hemochromatosis, a disorder of iron metabolism resulting in progressive iron accumulation in a variety of organs including the pancreas.
  • Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease.
  • This study determines the frequencies of p.C282Y and p.H63D alterations in patients with chronic pancreatitis and pancreatic adenocarcinoma.
  • METHODS: In total, 958 patients (349 with alcoholic pancreatitis, 343 with idiopathic pancreatitis, 64 with familial chronic pancreatitis, 34 with acute pancreatitis, and 168 with pancreatic adenocarcinoma) were enrolled and compared with 681 healthy and 100 alcoholic controls.
  • Genotyping of p.C282Y and p.H63D was performed by restriction fragment length polymorphism or melting curve analyses.
  • RESULTS: No significant differences were found in heterozygosity for p.C282Y and p.H63D when patients with alcoholic (8.0/21.5%), idiopathic (7.3/24.5%), or familial (9.8/23.0%) pancreatitis, or pancreatic adenocarcinoma (5.4/28.6%) were compared with healthy (6.2/24.8%) and alcoholic (7.0/25.0%) controls.
  • CONCLUSION: Although hemochromatosis is associated with pancreatic pathology, the p.C282Y and p.H63D variants do not play a significant role in the pathogenesis of chronic pancreatitis or pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Polymorphism, Restriction Fragment Length

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666895.001).
  • [ISSN] 1098-3600
  • [Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics
  • [ISO-abbreviation] Genet. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins
  •  go-up   go-down


55. Wang WJ, Li JG, Li ZT, Fang Q, Zheng YG: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for pancreatic adenocarcinoma. N Am J Med Sci; 2009 Jun;1(1):25-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for pancreatic adenocarcinoma.
  • A computed tomography scan demonstrated a 4cm×5cm×5cm solid space-occupying mass in the distal pancreas.
  • The patient was referred to minimally invasive surgery service for resection of the pancreatic lesion.
  • RESULTS: The mass was completely excised, the pathological examination revealed grade II pancreatic adenocarcinoma.
  • Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for pancreatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666667.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364626
  • [Keywords] NOTNLM ; Laparoscopy / adenocarcinoma / distal pancreatectomy / laparoscopic spleen-preserving / pancreas / pancreatectomy / pancreatic cancer / space-occupying / splenic vessels
  •  go-up   go-down


56. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR: Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol; 2008 Jan;23(1):23-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology of pancreatic adenocarcinoma: current status of imaging.
  • Pancreatic adenocarcinoma is one of the leading causes of cancer death in the West, with a poor overall 5-year survival rate of only 4%.
  • Tumor serum marker CA 19-9 is sensitive, although not specific for the diagnosis of adenocarcinomas of the pancreas.
  • Many modalities are available to image the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171340.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 66
  •  go-up   go-down


57. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS: 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery; 2008 Aug;144(2):141-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.
  • BACKGROUND: Acinar cell carcinoma (ACC) is a rare cancer of the pancreas accounting for approximately 1% of nonendocrine tumors.
  • OBJECTIVE: Our goal was to evaluate a large population-based cohort of patients with ACC and compare their demographic factors and outcomes to those of patients with pancreatic adenocarcinoma (PA).
  • The mean age at the time of diagnosis was significantly lower for ACC than PA (56 years vs 70 years, P < .001).
  • Multivariate Cox proportional hazards regression model results suggested patients with ACC were less likely to die (hazard ratio = 0.241; 95% confidence interval, 0.22-0.27) than patients with PA after controlling for gender, race, stage, SEER region of diagnosis, and surgical resection status.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656619.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA; 2007 May 2;297(17):1901-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
  • CONTEXT: While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been described, description of the role of miRNAs in ductal adenocarcinoma of the pancreas is lacking.
  • OBJECTIVE: To define the expression pattern of miRNAs in pancreatic cancer and compare it with those of normal pancreas and chronic pancreatitis.
  • DESIGN AND SETTING: Specimens were obtained at a National Cancer Institute-designated comprehensive cancer center from patients with ductal adenocarcinoma of the pancreas (n = 65) or chronic pancreatitis (n = 42) (January 2000-December 2005).
  • All patients underwent curative pancreatectomy; those with pancreatic cancer were chemotherapy-naive.
  • RNA harvested from resected pancreatic cancers and matched benign adjacent pancreatic tissue as well as from chronic pancreatitis specimens was hybridized to miRNA microarrays.
  • MAIN OUTCOME MEASURES: Identification of differentially expressed miRNAs that could differentiate pancreatic cancer from normal pancreas, chronic pancreatitis, or both, as well as a pattern of miRNA expression predictive of long-term (>24 months) survival.
  • RESULTS: Twenty-one miRNAs with increased expression and 4 with decreased expression were identified that correctly differentiated pancreatic cancer from benign pancreatic tissue in 90% of samples by cross validation.
  • Fifteen overexpressed and 8 underexpressed miRNAs differentiated pancreatic cancer from chronic pancreatitis with 93% accuracy.
  • CONCLUSIONS: Pancreatic cancer may have a distinct miRNA expression pattern that may differentiate it from normal pancreas and chronic pancreatitis. miRNA expression patterns may be able to distinguish between long- and short-term survivors, but these findings need to be validated in other study populations.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2007 May 2;297(17):1923-5 [17473304.001]
  • (PMID = 17473300.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081534; United States / NCI NIH HHS / CA / CA128609
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


59. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer; 2009 Feb 1;115(3):665-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
  • BACKGROUND: The authors report on the local control and toxicity of stereotactic body radiotherapy (SBRT) for patients with unresectable pancreatic adenocarcinoma.
  • METHODS: Seventy-seven patients with unresectable adenocarcinoma of the pancreas received 25 gray (Gy) in 1 fraction.
  • CONCLUSIONS: SBRT for pancreatic adenocarcinoma was effective for local control with associated risk of toxicity and should be used with rigorous attention to quality assurance.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [CommentIn] Cancer. 2009 Feb 1;115(3):468-72 [19117338.001]
  • (PMID = 19117351.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Airoldi M, Cattel L, Passera R, Pedani F, Milla P, Zanon C: Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas; 2006 Jan;32(1):44-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
  • OBJECTIVES: This phase 2 study evaluated clinical efficacy, toxicity, and pharmacokinetics of combination gemcitabine (GEM) and oxaliplatin (OXA) in patients with advanced pancreatic adenocarcinoma.
  • CONCLUSIONS: The combination of GEM and OXA was well tolerated and showed a promising activity in patients with advanced pancreatic adenocarcinoma; no sequence-dependent pharmacokinetic interaction occurred when comparing the GEM-OXA versus the OXA-GEM sequence, with a 24-hour interval.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Deoxycytidine / analogs & derivatives. Organoplatinum Compounds / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340743.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


61. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT: Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol; 2010;5:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.
  • PURPOSE: To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma.
  • Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%).
  • However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • (PMID = 21059255.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987939
  •  go-up   go-down


62. Sheibani-Rad S, Velanovich V: Effects of depression on the survival of pancreatic adenocarcinoma. Pancreas; 2006 Jan;32(1):58-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of depression on the survival of pancreatic adenocarcinoma.
  • OBJECTIVES: Depression frequently predates the diagnosis of pancreatic adenocarcinoma.
  • The purpose of this study was to assess whether survival after resection for pancreatic cancer is shortened by the pretreatment presence of depression.
  • METHODS: A database of all patients diagnosed with pancreatic cancer was retrospectively reviewed for depression, resection, and chemotherapy and/or radiation therapy.
  • RESULTS: The median survival time for all depressed patients with pancreatic cancer was 5 months compared with 4 months for all nondepressed patients with pancreatic cancer (P < 0.9).
  • Depression, although common among patients with pancreatic cancer, does not affect survival.
  • [MeSH-major] Adenocarcinoma / psychology. Depression / epidemiology. Pancreatic Neoplasms / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340745.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chan M, Scaife C, Thaker HM, Adler DG: Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound. JOP; 2009;10(5):554-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound.
  • CONTEXT: Patients with known or suspected pancreatic adenocarcinoma are typically evaluated with noninvasive imaging studies and endoscopic ultrasound.
  • Some patients have pancreatic adenocarcinomas that cannot be detected using any of these methods.
  • Multiple endoscopic ultrasound and triple phase pancreatic protocol CT exams were negative for a mass lesion and revealed a normal pancreas.
  • Intraoperative ultrasound of the pancreas was also felt to be normal.
  • Intraoperative biopsy of the head of the pancreas revealed a small, moderately to poorly differentiated adenocarcinoma, not visible on any of her imaging studies.
  • CONCLUSION: Some pancreatic adenocarcinomas may defy detection using modern imaging modalities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Errors. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde / methods. Delayed Diagnosis. Endosonography / methods. Female. Humans. Intraoperative Period. Middle Aged. Tomography, X-Ray Computed / methods. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734637.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


64. Takamori H, Kanemitsu K, Tsuji T, Kusano S, Chikamoto A, Okuma T, Iyama K: Metastatic gastric tumor secondary to pancreatic adenocarcinoma. J Gastroenterol; 2005 Feb;40(2):209-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastric tumor secondary to pancreatic adenocarcinoma.
  • Metastatic disease, from the pancreas, involving the stomach is an unusual clinical event.
  • Local recurrence, liver metastases, and peritoneal spread are the most common recurrent patterns after curative resection of pancreatic cancer.
  • We report a patient who suffered from gastric metastasis secondary to pancreatic adenocarcinoma 1 year after pancreatectomy.
  • A 49-year-old woman underwent distal pancreatectomy with intraoperative radiation therapy for cancer of the body of the pancreas in October 2002.
  • The histological diagnosis was well-differentiated adenocarcinoma of the pancreas, stage IIB; T1N1M0.
  • Histological diagnosis of the biopsy specimen was well-differentiated adenocarcinoma, and immunohistochemical studies, using anti-cytokeratin 7 and -20 monoclonal antibodies, were compatible with gastric metastasis from pancreatic carcinoma.
  • Histopatholoical examination of the resected specimen revealed submucosal growth of the metastatic cancer (well-differentiated adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770407.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


65. Morales A, Vilchis F, Chávez B, Chan C, Robles-Díaz G, Díaz-Sánchez V: Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma. J Steroid Biochem Mol Biol; 2007 Oct;107(1-2):37-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma.
  • Since the human pancreatic cells retain steroidogenic activity, in the present study we ascertained whether this angiogenic factor is expressed in normal pancreas and pancreatic adenocarcinoma.
  • The relative amount of EG-VEGF mRNA in pancreas was more abundant in female adenocarcinoma (0.89) followed by male adenocarcinoma (0.71), than normal female (0.64) and normal male (0.38).
  • In male preparations, the positive labeling was localized predominantly within the pancreatic islets while in female preparations the main staining was detected towards the exocrine portion.
  • Specific immunolabeling was also observed in endothelial cells of pancreatic blood vessels.
  • Our data provide evidence that the human pancreas expresses the EG-VEGF, a highly specific mitogen which regulates proliferation and differentiation of the vascular endothelium.
  • The significance of this finding could be interpreted as either, EG-VEGF is not exclusive of endocrine organs, or the pancreas should be considered as a functional steroidogenic tissue.
  • The extent of the expression of EG-VEGF appears to have a dimorphic pattern in normal and tumoral pancreatic tissue.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastrointestinal Hormones / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. RNA, Messenger / metabolism. Vascular Endothelial Growth Factor, Endocrine-Gland-Derived / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683928.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrointestinal Hormones; 0 / PROK1 protein, human; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor, Endocrine-Gland-Derived
  •  go-up   go-down


66. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg; 2007 Jul;246(1):52-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
  • OBJECTIVE: To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma.
  • Standard pathologic evaluation of the PD specimen included permanent section analysis of the final bile duct, pancreatic, and superior mesenteric artery (SMA) margins.
  • Survival and follow-up were calculated from the date of initial histologic diagnosis to the dates of first recurrence or death and last contact, respectively.
  • RESULTS: PD was performed on 360 consecutive patients with pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2000 May-Jun;52(3):263-70 [10932371.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):47-55 [11420482.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Eur J Surg Oncol. 1991 Apr;17(2):173-81 [2015922.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]
  • [Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):39-49 [9300738.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [CommentIn] Ann Surg. 2008 Apr;247(4):716-7 [18362643.001]
  • (PMID = 17592291.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / 1 P20 CA101936-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899216
  •  go-up   go-down


67. Ujiki MB, Talamonti MS: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol; 2007 Aug;34(4):311-20
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the surgical management of pancreatic adenocarcinoma.
  • Despite these advances, morbidity and mortality after pancreaticoduodenectomy are not insignificant and the overall prognosis following resection for adenocarcinoma of the pancreas remains poor.
  • This article will attempt to describe current guidelines for the preoperative, intraoperative, and postoperative management of patients with localized pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674959.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


68. Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, Schmidt CM, Nakeeb A, Matos JM, Scoggins CR, Martin RC, Kim HJ, Ahmad SA, Chu CK, McClaine R, Bednarski BK, Staley CA, Sharp K, Parikh AA: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg; 2009 May;208(5):829-38; discussion 838-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?
  • BACKGROUND: The role of adjuvant chemoradiation therapy (CRT) in pancreatic cancer remains controversial.
  • The primary aim of this study was to determine if CRT improved survival in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients.
  • STUDY DESIGN: Patients undergoing resection for pancreatic adenocarcinoma from seven academic medical institutions were included.
  • CONCLUSIONS: This large multiinstitutional study emphasizes the importance of analyzing subsets of patients with pancreas adenocarcinoma who have LN metastasis.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):74-85 [12496533.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2081-8 [18461404.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4532-7 [16002844.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2773-86 [18612703.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • (PMID = 19476845.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA098240
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS627213; NLM/ PMC4167601
  •  go-up   go-down


69. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg; 2008 Mar;247(3):456-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
  • OBJECTIVE: To determine long-term survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma and to identify clinical factors associated with long-term survival.
  • SUMMARY BACKGROUND DATA: The prognosis for long-term survival even after potentially curative resection for pancreatic adenocarcinoma is thought to be poor.
  • Clinical factors determining short-term survival after pancreatic resection are well studied, but prognostic factors predicting long-term survival with a potential for cure are poorly understood.
  • METHODS: A case-control study was conducted of 357 patients who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 1981 and 2001.
  • Histologic specimens were reanalyzed to confirm diagnosis.
  • Five-year survival was no guarantee of cure because 16% of this subset died of pancreatic cancer up to 7.8 years after operation.
  • CONCLUSION: Pancreatoduodenectomy for adenocarcinoma in the head of pancreas can provide long-term survival in a subset of patients, particularly in the absence of lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376190.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


70. Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G: Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):97-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
  • BACKGROUND: The association between gastric and pancreatic carcinoma is a relatively rare condition.
  • Gastric cancer associated with pancreatic cancer is uncommon.
  • Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the pancreas.
  • Histological examination of the specimen demonstrated a moderately differentiated adenocarcinoma of the stomach and a poorly differentiated ductal adenocarcinoma of the pancreas.
  • CONCLUSIONS: Long survival is rare in patients with associated gastric and pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133238.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Bass LM, Patil D, Rao MS, Green RM, Whitington PF: Pancreatic adenocarcinoma in type 2 progressive familial intrahepatic cholestasis. BMC Gastroenterol; 2010;10:30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in type 2 progressive familial intrahepatic cholestasis.
  • CASE PRESENTATION: A 36 year old woman with BSEP disease developed pancreatic adenocarcinoma at age 36.
  • A 1.7 x 1.3 cm mass was detected in the pancreas on abdominal CT scan.
  • A 2 cm mass lesion was found at the neck and proximal body of the pancreas.
  • Pathology demonstrated a grade 2-3 adenocarcinoma with invasion into the peripancreatic fat.
  • CONCLUSIONS: Clinicians should be aware of the possibility of pancreatic adenocarcinoma in patients with BSEP disease.
  • [MeSH-major] Adenocarcinoma / etiology. Cholestasis, Intrahepatic / complications. Pancreatic Neoplasms / etiology


72. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Béllannée G, Brunet R, Collet D, Masson B: Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg; 2005 Sep;201(3):359-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
  • BACKGROUND: The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors.
  • This article reports our experience with chemoradiotherapy for patients with unresectable, locally advanced pancreatic cancer (superior mesenteric artery or celiac axis encasement).
  • STUDY DESIGN: Since 1998, 61 patients with radiographically unresectable, pathologically confirmed pancreatic adenocarcinoma have received standard fractionation radiation therapy (total dose, 45 Gy at 1.8 Gy, 5 d/wk) with chemotherapy, which included a continuous infusion of fluorouracil (5-FU: 650 mg/m(2)/D1-D5 and D21-D25) and cisplatin (80 mg/m(2)/bolus D2 and D22).
  • CONCLUSIONS: Locally advanced, unresectable pancreatic adenocarcinoma may be downstaged by chemoradiotherapy to allow for surgical resection.
  • Patients whose cancer becomes resectable have a median survival at least comparable with survival after resection for initially resectable pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / therapy. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Neoplasm Staging. Palliative Care. Pancreas / pathology. Radiotherapy Dosage. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M: MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol; 2010 Dec;17(12):3120-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.
  • BACKGROUND: Detection of aberrant microRNA (miR) expression may contribute to diagnosis and prognosis of various cancers.
  • The aim of this study is to evaluate the correlation between miR-203 expression and prognosis of patients with pancreatic adenocarcinoma after curative resection.
  • METHODS: A total of 113 formalin-fixed paraffin-embedded tissue samples of pancreatic adenocarcinoma, 20 samples of chronic pancreatitis, and 8 samples of normal pancreas were obtained.
  • RESULTS: miR-203 was overexpressed in pancreatic adenocarcinoma samples compared with chronic pancreatitis (P < 0.001) and normal pancreas (P = 0.001) samples.
  • An association between miR-203 expression and clinicopathological factors of pancreatic adenocarcinoma was not observed.
  • CONCLUSIONS: miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. MicroRNAs / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / metabolism. Pancreas / pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20652642.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN203 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


74. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD: Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas; 2008 Aug;37(2):154-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
  • OBJECTIVES: Given the extensive desmoplastic response associated with pancreatic adenocarcinoma, we hypothesized that the stromal protein fibroblast activation protein (FAP) would be highly expressed and associated with the presence of fibrosis and other clinical features.
  • METHODS: Paraffin-embedded pancreatic adenocarcinomas that were resected with curative intent from 1992 to 2003 were used for this study.
  • CONCLUSIONS: Fibroblast activation protein is highly expressed in pancreatic adenocarcinoma, with greatest expression immediately adjacent to tumor.
  • The investigation of FAP inhibitors as a therapeutic strategy against pancreatic cancer should be considered.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Pancreatic Neoplasms / metabolism. Serine Endopeptidases / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665076.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


75. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR: Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A; 2006 Oct;16(5):458-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with pancreatic adenocarcinoma benefit from staging laparoscopy.
  • BACKGROUND: Unnecessary laparotomy in patients with advanced pancreatic cancer may both compromise the quality of life and delay the initiation of more appropriate therapy.
  • The aim of this study was to determine the impact of laparoscopy in patients with potentially resectable adenocarcinoma of the pancreas.
  • MATERIALS AND METHODS: We reviewed the records of patients undergoing pancreatic surgery at the University of Nebraska Medical Center from October 2001 to April 2005.
  • Of those, 24 patients (85.7%) underwent pancreatic resection with curative intent, while 4 patients had metastatic or locally advanced disease at subsequent laparotomy which was missed on staging laparoscopy (false negative rate of 14.3%).
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004868.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Jamal MH, Doi SA, Simoneau E, Abou Khalil J, Hassanain M, Chaudhury P, Tchervenkov J, Metrakos P, Barkun JS: Unresectable pancreatic adenocarcinoma: do we know who survives? HPB (Oxford); 2010 Oct;12(8):561-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresectable pancreatic adenocarcinoma: do we know who survives?
  • BACKGROUND: This study attempts to define clinical predictors of survival in patients with unresectable pancreatic adenocarcinoma (UPA).
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Hepato-Pancreato-Biliary Association.
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6):835-41 [12447294.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):194-205 [19856029.001]
  • [Cites] Ann Surg. 1994 Jan;219(1):18-24 [7507656.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Cancer. 1996 Aug 1;78(3 Suppl):605-14 [8681299.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):470-5 [8876889.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):833-9 [9684143.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1271-8 [10235206.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] World J Surg. 2005 Apr;29(4):519-23 [15770375.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Sep;21(5):601-5 [16093777.001]
  • [Cites] Clin Nutr. 2005 Dec;24(6):998-1004 [16140426.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):366-70 [11868010.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):735-42 [16635221.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2589-96 [17083124.001]
  • [Cites] JOP. 2007;8(2):240-53 [17356251.001]
  • [Cites] Pancreas. 2007 Apr;34(3):335-9 [17414056.001]
  • [Cites] Dig Dis. 2007;25(3):285-8 [17827959.001]
  • [Cites] J Clin Gastroenterol. 2008 Jan;42(1):86-91 [18097296.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):91-100 [17786524.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):221-8 [18154768.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3138-46 [18787902.001]
  • [Cites] Dig Surg. 2009;26(1):75-9 [19169034.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • (PMID = 20887324.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2997662
  •  go-up   go-down


77. Roy R, Maraveyas A: Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist; 2010;15(3):259-69
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in pancreatic adenocarcinoma: a literature review.
  • Adenocarcinoma of the exocrine pancreas has an annual incidence of 7,400 cases in the U.K.
  • In comparison with other common cancers of solid organs, namely, breast, colorectal, and prostate cancer, pancreatic cancer has a high morbidity and mortality.
  • In this article, we review the published literature on the use of chemoradiation as a modality in various stages of pancreatic adenocarcinoma and highlight areas that future trials in this field should target for a way forward in this malignancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Can Assoc Radiol. 1981 Sep;32(3):164-5 [7028759.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):373-8 [3973648.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2563-8 [2864997.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1110-6 [3342371.001]
  • [Cites] J Natl Cancer Inst. 1988 Jul 20;80(10):751-5 [2898536.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1145-9 [1657839.001]
  • [Cites] Arch Surg. 1992 Nov;127(11):1335-9 [1359851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1153-7 [8262841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):207-11 [8270443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • [Cites] Arch Surg. 1994 Oct;129(10):1075-80 [7944938.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):71-7; discussion 77-8 [7818001.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2764-8 [7595736.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5 [8554125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):867-72 [8598364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):351-6 [8635943.001]
  • [Cites] Invest New Drugs. 1996;14(3):257-63 [8958180.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):39-49 [9300738.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6):715-31 [9422267.001]
  • [Cites] Oncology (Williston Park). 1997 Nov;11(11A):41-55 [9430178.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):355-60 [10440189.001]
  • [Cites] Radiology. 1965 May;84:843-8 [14282693.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Radiother Oncol. 2005 Jul;76(1):48-53 [15990186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 [16168826.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):332-3; author reply 333 [16858208.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):326-31 [17235048.001]
  • [Cites] Eur Radiol. 2007 Mar;17(3):638-49 [17021700.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1027-36 [17197132.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):47-55 [17538975.001]
  • [Cites] Pancreas. 2008 Jan;36(1):e26-32 [18192876.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Sep;20(7):535-40 [18346883.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1592-9 [18467316.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):295-307 [18813197.001]
  • [Cites] Am J Clin Oncol. 2008 Dec;31(6):545-52 [19060585.001]
  • [Cites] Singapore Med J. 2009 Jan;50(1):43-8 [19224083.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Arch Surg. 2000 Jan;135(1):81-7; discussion 88 [10636353.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):155-9 [11319291.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4202-8 [11709563.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):758-65 [11776488.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302 [11955742.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):146-50 [12007953.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):137-41 [12182983.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):30-6 [12576921.001]
  • [Cites] Strahlenther Onkol. 2003 Feb;179(2):78-86 [12590317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):10-5 [12826246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104 [12909221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):502-10 [15120377.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):445-53 [15145161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9 [15145162.001]
  • [Cites] Am J Clin Oncol. 2004 Aug;27(4):343-9 [15289726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52 [15380578.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Cancer. 1976 Mar;37(3):1519-24 [1260670.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • (PMID = 20203172.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3227952
  •  go-up   go-down


78. Hattori Y, Gabata T, Matsui O, Mochizuki K, Kitagawa H, Kayahara M, Ohta T, Nakanuma Y: Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol; 2009 Jul 7;15(25):3114-21
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis.
  • AIM: To evaluate retrospectively the correlation between enhancement patterns on dynamic computed tomography (CT) and angiogenesis and fibrosis in pancreatic adenocarcinoma.
  • METHODS: Twenty-three patients with pancreatic adenocarcinoma underwent dynamic CT and tumor resection.
  • In addition to the absolute and relative enhanced value that was calculated by subtracting the attenuation value on pre-contrast from those on contrast-enhanced CT in each phase, we defined one parameter, "tumor-aorta enhancement ratio", which was calculated by dividing enhancement of pancreatic cancer by enhancement of abdominal aorta in each phase.
  • [MeSH-major] Adenocarcinoma. Image Enhancement. Neovascularization, Pathologic. Pancreatic Neoplasms. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10):1981-7 [17893216.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):315-8 [17551312.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):44-53 [18055062.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Radiology. 2001 Aug;220(2):548-53 [11477267.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5381-5 [12235011.001]
  • [Cites] Radiology. 2003 Feb;226(2):345-54 [12563124.001]
  • [Cites] Pancreas. 2003 May;26(4):344-9 [12717266.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):2100-4 [12970915.001]
  • [Cites] Radiology. 2004 Oct;233(1):191-9 [15304661.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):33-41 [7541612.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):193-204 [8534867.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1230-7 [8908556.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):980-5 [9386294.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1309-16 [9815813.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):131-8 [15523683.001]
  • [Cites] Radiology. 2005 Mar;234(3):785-92 [15734934.001]
  • [Cites] Radiology. 2005 Oct;237(1):151-8 [16183931.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):280-6 [16482630.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Pancreas. 2006 Apr;32(3):271-5 [16628082.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5):1423-30 [16632740.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1823-32 [16773076.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):919-26 [17008987.001]
  • [Cites] Clin Imaging. 2007 May-Jun;31(3):165-77 [17449377.001]
  • [Cites] Radiology. 2007 Jun;243(3):736-43 [17517931.001]
  • [Cites] Clin Radiol. 2008 Feb;63(2):153-9 [18194690.001]
  • (PMID = 19575490.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2705733
  •  go-up   go-down


79. Masellis AM, Sielaff TD, Bender GP: Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol; 2009 Oct;14(5):478-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
  • Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States.
  • We report the case of a 41-year-old woman who was diagnosed with advanced metastatic well-to-moderately differentiated mucinous adenocarcinoma of the pancreas, involving the liver and peritoneal cavity.
  • Complete response of multiple liver and peritoneal metastases and reduction in size with increasing calcification of the pancreatic mass occurred in this patient after 18 months of treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856062.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 130-nm albumin-bound paclitaxel; 0 / Albumins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Jarry J, Belleannee G, Rault A, Sa Cunha A, Collet D: Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas? JOP; 2010;11(1):55-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas?
  • CONTEXT: Despite the recent progress of diagnostic and therapeutic modalities, survival rates of pancreatic adenocarcinoma remain poor, mainly due to late diagnosis.
  • CASE REPORT: We report the case of a 56-year-old man who was diagnosed with a symptomatic intraductal papillary mucinous tumor of the pancreas located in the uncus.
  • This tumor was associated with a concurrent stenosis of the isthmic pancreatic duct which resulted in a distal dilation.
  • During the procedure, a concomitant adenocarcinoma was diagnosed 2 cm from the primary intraductal papillary mucinous tumor, causing the isthmic stenosis.
  • A second resection was then performed to the left of the pancreatic isthmus, and adjuvant chemotherapy was performed.
  • CONCLUSION: We discuss the possibility that intraductal papillary mucinous tumors may be a "red flag" enabling earlier diagnosis of a concurrent pancreatic adenocarcinoma arising in another area of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Early Detection of Cancer. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065554.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Lin YH, Chen CY, Chen CP, Kuo TY, Chang FY, Lee SD: Hematemesis as the initial complication of pancreatic adenocarcinoma directly invading the duodenum: a case report. World J Gastroenterol; 2005 Feb 7;11(5):767-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematemesis as the initial complication of pancreatic adenocarcinoma directly invading the duodenum: a case report.
  • Pancreatic carcinoma is a debilitating disease and carries a poor prognosis.
  • It is a rare cause of upper gastrointestinal bleeding, even though pancreas, stomach, duodenum and jejunum are adjacent organs.
  • The incidence of pancreatic adenocarcinoma directly invading the gastrointestinal tract leading to gastrointestinal hemorrhage is very low, and most of them present with melena and hematochezia.
  • Here, we describe one unique case manifesting characteristically severe and unremitting hematemesis as an initial presentation of pancreatic adenocarcinoma.
  • Our MEDLINE search has confirmed that this is the first reported case with an initial manifestation of hematemesis from pancreatic adenocarcinoma in Asians.
  • Pancreatic adenocarcinoma directly invading duodenum complicated by hemorrhage can be a rare cause of hematemesis, and clinicians should be reminded of it while they are making differential diagnosis.
  • [MeSH-major] Adenocarcinoma / complications. Duodenum / pathology. Hematemesis / etiology. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655842.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250759
  •  go-up   go-down


82. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol; 2007 Jun;20(6):656-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
  • Pancreatic adenocarcinomas are highly invasive cancers for reasons that are currently unclear.
  • Here we sought to determine if the proinvasive integrin alpha6beta4 may be related to pancreatic adenocarcinoma tumor progression.
  • Expression of integrin alpha6beta4 was analyzed via immunohistochemistry for the beta4 subunit in normal pancreas, pancreatic intraepithelial neoplasia (PanIN) lesions, pancreatic adenocarcinomas and chronic pancreatitis.
  • In normal pancreatic ducts, integrin alpha6beta4 was noted only at the cell's basal interface with the basement membrane.
  • In pancreatic adenocarcinomas, 92% (104/113) demonstrated overexpression of integrin alpha6beta4 and altered localization to the cytoplasm and membranous regions.
  • In contrast, 93% (13/14) of chronic pancreatitis samples resembled the staining pattern of normal pancreas.
  • We conclude that integrin alpha6beta4 is expressed only on the basal surface of ductal cells in normal pancreas and chronic pancreatitis.
  • During pancreatic adenocarcinoma progression, the alpha6beta4 integrin is dramatically overexpressed and displays altered localization at the earliest stages of PanIN, thus representing an early event in pancreatic adenocarcinoma progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415382.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
  • [Other-IDs] NLM/ NIHMS517144; NLM/ PMC4697742
  •  go-up   go-down


83. Sorg C, Schmidt J, Büchler MW, Edler L, Märten A: Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma. Pancreas; 2009 Jul;38(5):542-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma.
  • Randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma with an evidence level of lower than 2 were selected and evaluated for internal and external validities focusing on selection bias.
  • RESULTS: Four selected trials (European Study Group for Pancreatic Cancer 1 [ESPAC-1], Charité Onkologie Clinical Studies in GI Cancer 001 [CONKO 001], Radiation Therapy Oncology Group 97-04 [RTOG 97-04], and Adjuvant Chemoradioimmunotherapy of Pancreatic Carcinoma [CapRI]) proved to be evaluable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. Randomized Controlled Trials as Topic / standards. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287330.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Turrini O, Viret F, Moureau L, Guiramand J, Lelong B, Bège T, Giovannini M, Delpero JR: [A modified Dworak classification applied to pancreatic adenocarcinoma: a useful prognostic factor]. Bull Cancer; 2007 Oct;94(10):897-901
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A modified Dworak classification applied to pancreatic adenocarcinoma: a useful prognostic factor].
  • [Transliterated title] La classification de Dworak: du rectum au pancréas.
  • Between 1996 and 2005, 56 non metastatics patients had preoperative chemoradiation and curative resection for pancreatic adenocarcinoma.
  • Thus, adenocarcinoma of the pancreas had to be treated by surgical curative resection associated with radiotherapy and systemic chemotherapy to control the both side, metastatic and local, of the disease.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964983.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Validation Studies
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


85. Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S: Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol; 2007 Mar;35(3):143-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
  • Mesothelin is a potential marker of pancreatic adenocarcinoma that was recently identified by serial analysis of gene expression.
  • We evaluated the sensitivity and specificity of mesothelin as a marker of pancreatic adenocarcinoma on destained Papanicolaou (Pap) smears and unstained cellblocks from 28 patients using a monoclonal antibody to mesothelin.
  • Focal positivity for mesothelin was noted in benign pancreatic tissue in one of 10 cases.
  • The overall sensitivity and specificity of mesothelin as a marker for pancreatic adenocarcinoma were 68% and 90%, respectively.
  • The presence of occasional mesothelin expression in benign tissue, its very focal expression in malignant tissue may limit the utility of mesothelin as a marker of pancreatic adenocarcinomas in fine-needle aspiration (FNA) specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Membrane Glycoproteins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Pancreas / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304533.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


86. Hijioka S, Ikari T, Kamei A, Takano K, Asahara S, Fujita N, Shimizu M, Yamamoto J, Fujita R, Sasaki K: CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase. Hepatogastroenterology; 2007 Mar;54(74):389-92
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase.
  • Dynamic computed tomography and magnetic resonance imaging demonstrated a mass in the body of the pancreas, which was enhanced in the late phase of the scans by administration of a contrast medium.
  • Endoscopic retrograde pancreatography showed a stenosis of the main pancreatic duct at the body, and brushing cytology from the region revealed adenocarcinoma.
  • The tumor was a well-differentiated adenocarcinoma, measuring 15 x l0 mm.
  • Marked tumor enhancement in the late phase might be a characteristic finding suggesting an early-stage pancreatic adenocarcinoma, which should be carefully checked.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis. Tomography, Spiral Computed
  • [MeSH-minor] Amylases / blood. Contrast Media / administration & dosage. Female. Gadolinium DTPA. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Pancreas / pathology. Pancreatectomy. Pancreatic Ducts / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523281.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media; EC 3.2.1.- / Amylases; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


87. Cress RD, Yin D, Clarke L, Bold R, Holly EA: Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control; 2006 May;17(4):403-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States).
  • OBJECTIVE: The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.
  • METHODS: Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000.
  • CONCLUSIONS: This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596292.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108370; United States / NCI NIH HHS / CA / CA59706; United States / PHS HHS / / U75-CCU910677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


89. Faccioli N, D'Onofrio M, Malagò R, Zamboni G, Falconi M, Capelli P, Mucelli RP: Resectable pancreatic adenocarcinoma: depiction of tumoral margins at contrast-enhanced ultrasonography. Pancreas; 2008 Oct;37(3):265-8
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable pancreatic adenocarcinoma: depiction of tumoral margins at contrast-enhanced ultrasonography.
  • To evaluate if contrast-enhanced ultrasonography (CEUS) improves the depiction of tumoral margins of pancreatic adenocarcinoma in relation to tumor enhancement, using pathology as criterion standard.
  • METHODS: Two hundred forty-one patients affected by pancreatic ductal adenocarcinoma were investigated at CEUS with a second-generation contrast medium of sulfur-hexafluoride microbubbles.
  • CONCLUSIONS: At CEUS the depiction of tumoral margins of pancreatic adenocarcinoma is more accurate in low enhancement than in high enhancement.
  • The pattern of enhancement of pancreatic adenocarcinoma influences the depiction of tumoral margins at CEUS.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / ultrasonography. Contrast Media. Pancreatectomy. Pancreatic Neoplasms / ultrasonography. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815547.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


90. Gleason B, Adley B, Rao MS, Diaz LK: Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem; 2005 Jun;53(6):799-801
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma.
  • The expression of the beta4 integrin subunit protein in pancreatic cancer was investigated using routine immunohistochemical methods on paraffin-embedded archival material.
  • Forty-eight cases of pancreatic ductal adenocarcinoma were immunostained with a monoclonal antibody to the beta4 integrin subunit, and the extent of staining was compared with that seen in non-cancerous pancreatic tissues, including 15 separate cases of chronic pancreatitis and 6 sections from normal pancreas.
  • We found that the beta4 integrin subunit protein was overexpressed in the majority of pancreatic carcinoma cases tested, whereas chronic pancreatitis and normal pancreas did not display substantial levels of expression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Integrin beta4 / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928331.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin beta4; 0 / Protein Subunits
  •  go-up   go-down


91. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA: Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg; 2008 Dec;143(12):1166-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss.
  • HYPOTHESIS: Although the safety of pancreaticoduodenectomy has notably improved over the past several decades, the reported survival of patients with pancreatic cancer remains poor.
  • We hypothesized that, in recent years, the survival of patients with pancreatic adenocarcinoma following pancreaticoduodenectomy has substantially improved.
  • SETTING: Major academic medical and pancreatic surgery center.
  • INTERVENTIONS: Pancreaticoduodenectomy for patients with a diagnosis of pancreatic adenocarcinoma.
  • RESULTS: During the time period analyzed, 182 patients underwent pancreaticoduodenectomy to treat ductal adenocarcinoma.
  • CONCLUSIONS: The survival rate for patients undergoing pancreaticoduodenectomy to treat pancreatic cancer has substantially improved.
  • [MeSH-major] Adenocarcinoma / surgery. Blood Loss, Surgical / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2009 Jun;144(6):594; author reply 594-5 [19528398.001]
  • (PMID = 19075167.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Guo JH, Wang WJ, Liao P, Zhang CY, Jin DY, Lou WH, Zhang SC: [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):33-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
  • OBJECTIVE: To establish decision tree and logistic regression classification models for diagnosing pancreatic adenocarcinoma (PaCa) and for screening serum biomarkers related to evaluation of different stages and curative effects.
  • METHODS: Serum samples obtained from subjects with pancreatic adenocarcinoma (n = 58) and normal pancreas (n = 51) were applied to strong anion exchange chromatography (SAX2) chips for protein profiling by SELDI-TOF-MS to screen multiple serum biomarkers.
  • RESULTS: Average of 61 mass peaks were detected at the molecular range of 2000-30,000, ten decision trees with the highest cross validation rate were chosen to construct the classification models, which can differentiate PaCa from normal pancreas with a sensitivity of 83.3% and a specificity of 100%.
  • CONCLUSION: Decision tree and logistic regression classification models of the mass peaks screened by SELDI-TOF-MS serum profiling can be used to differentiate pancreatic adenocarcinoma from normal pancreas, and is superior to CA 199.
  • The detected mass peaks are helpful for the evaluation of curative effect and prognosis of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Blood Proteins / analysis. Pancreatic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211064.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


93. Shamamian P, Goldberg JD, Ye XY, Stewart JD, White PJ, Gilvarg C: Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. HPB (Oxford); 2006;8(6):451-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas.
  • BACKGROUND: A serological marker for pancreatic cancer may allow for early detection and potentially more effective treatments.
  • Pro-carboxypeptidase A (pro-CPA) is produced exclusively in the pancreas and converted to its active form, CPA, in the intestinal lumen.
  • We hypothesized that alterations in serum pro-CPA and/or CPA may be useful as a diagnostic test for pancreatic cancer.
  • PATIENTS AND METHODS: Serum samples obtained from 34 patients with pancreatic adenocarcinoma prior to surgical intervention and 64 control patients were assayed for pro-CPA and CPA.
  • A variety of statistical methods was used to evaluate the utility of these measurements individually and in combination to classify the samples with respect to the presence or absence of pancreatic adenocarcinoma.
  • All pancreatic cancer patients had ln(CPA) levels within or below the normal range defined as two standard deviations from the control group mean (-2.714+/-0.413).
  • Pancreatic cancer patients with ln pro-CPA values within the control range had low ln CPA, advanced stage and/or evidence of pancreatic insufficiency.
  • While each of these individual values (ln pro-CPA or ln CPA) does not adequately separate all control from cancer patients, a bivariate classification rule is presented that uses both ln pro-CPA and ln CPA simultaneously to predict the presence of pancreatic cancer with a sensitivity of 91% and a specificity of 95%.
  • CONCLUSIONS: The data presented suggest that abnormalities in serum pro-CPA and CPA levels are associated with the presence of pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):103-24 [9443989.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):639-43 [9416411.001]
  • [Cites] Clin Chim Acta. 1999 Mar;281(1-2):19-28 [10217623.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):506-11 [10482707.001]
  • [Cites] Clin Chim Acta. 2000 Feb 25;292(1-2):107-15 [10686280.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):207-29, x [11930875.001]
  • [Cites] Clin Chem. 1989 Feb;35(2):251-5 [2464445.001]
  • [Cites] Anal Biochem. 1987 Feb 15;161(1):219-25 [3578784.001]
  • [Cites] Clin Chim Acta. 1983 Nov 30;135(1):65-71 [6197212.001]
  • [Cites] Anal Biochem. 1982 Sep 15;125(2):420-6 [7181100.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Surg Oncol. 1996 Apr;5(2):49-63 [8853239.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):106-12 [9834336.001]
  • (PMID = 18333101.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020764
  •  go-up   go-down


94. Vadalà S, Aronica G, Biondi A, Magnano V, Valastro M, Li Volti G, Cordio S, Giannone G: Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma. Clin Ter; 2009;160(4):287-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma.
  • Subsequently, Mayumi et al. and Kimura et al. adopted this approach for locally advanced adenocarcinoma of pancreatic body.
  • We are here describing this technique in case of adenocarcinoma of pancreatic body with infiltration of celiac axis achieving also gastric preservation.
  • CT scan showed a 3 cm mass in the body of pancreas infiltrating the origin of celiac axis, causing obstructive atrophy of pancreatic tail.
  • Appleby operation can increase the resectability of locally advanced cancer of the body and tail of the pancreas and offers not only a better life quality for patients but also perfect pain relief.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795078.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


95. Haas SL, Jesnowski R, Steiner M, Hummel F, Ringel J, Burstein C, Nizze H, Liebe S, Löhr JM: Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol; 2006 Aug 14;12(30):4843-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.
  • AIM: To study expression of tissue factor (TF) in pancreatic cancer and its role in the development of thromboembolism.
  • METHODS: TF expression was studied in eight human pancreatic carcinoma cell lines by Northern blot and indirect immunofluorescence.
  • In addition, TF expression was determined by immunofluorescence in pancreatic tissues of 19 patients with pancreatic adenocarcinoma (PCa), 9 patients with chronic pancreatitis (CP) and 20 normal controls.
  • RESULTS: All pancreatic carcinoma cell lines expressed TF (8/8) and most of them expressed asTF (6/8).
  • All but two pancreatic cancer tissue samples stained positive for TF (17/19).
  • In all samples of CP weak staining was restricted to pancreatic duct cells, whereas only a few subendothelial cells were positive in 9/20 of normal controls.
  • CONCLUSION: We conclude that in addition to the upregulated expression of TF on the cell membrane, soluble TF might contribute to activation of the coagulation system in pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Blood Coagulation. Pancreatic Neoplasms / metabolism. Thromboembolism / metabolism. Thromboplastin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Apr;9(4):458-62 [12652293.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Virchows Arch. 2003 May;442(5):444-52 [12692724.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):417-22 [12798743.001]
  • [Cites] Chest. 2003 Sep;124(3 Suppl):58S-68S [12970125.001]
  • [Cites] Crit Care Med. 2004 May;32(5 Suppl):S293-7 [15118533.001]
  • [Cites] Nat Med. 2004 May;10(5):502-9 [15098027.001]
  • [Cites] Thromb Haemost. 2004 Jul;92(1):132-9 [15213854.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):92-5 [15226761.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):36142-7 [15201277.001]
  • [Cites] Histopathology. 1985 Aug;9(8):841-56 [2997015.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):472-7 [10027315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-5 [10051638.001]
  • [Cites] Atherosclerosis. 1999 Jun;144(2):273-83 [10407489.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] J Thromb Haemost. 2004 Nov;2(11):2065-7 [15550054.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):47-56 [15569823.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1734-41 [15494427.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2531-9 [15814630.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1604-11 [15741221.001]
  • [Cites] Cell. 1987 Jul 3;50(1):129-35 [3297348.001]
  • [Cites] Am J Pathol. 1989 May;134(5):1087-97 [2719077.001]
  • [Cites] Thromb Res. 1990 Jul 15;59(2):421-37 [2237820.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15719-25 [1874730.001]
  • [Cites] N Engl J Med. 1992 May 7;326(19):1240-5 [1560799.001]
  • [Cites] J Neurosci. 1992 Dec;12(12):4905-10 [1281498.001]
  • [Cites] Pancreas. 1993 Mar;8(2):248-54 [8460098.001]
  • [Cites] Br J Cancer. 1994 Jan;69(1):144-51 [8286197.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1320-7 [7521887.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):3849-57 [7876129.001]
  • [Cites] FASEB J. 1995 Jul;9(10):883-9 [7615158.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1101-4 [7648165.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26419-32 [7592857.001]
  • [Cites] Nat Med. 1996 Feb;2(2):209-15 [8574967.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):356-67 [10648464.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1627-32 [10821379.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):164-70 [10901365.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):550-5 [11212248.001]
  • [Cites] Circulation. 2001 Jun 26;103(25):3044-6 [11425765.001]
  • [Cites] J Gastroenterol. 2001 Dec;36(12):848-50 [11777214.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Curr Opin Hematol. 2002 Sep;9(5):401-6 [12172458.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):1-7 [8644983.001]
  • [Cites] Pancreas. 1996 Apr;12(3):248-59 [8830331.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):121-5 [9198140.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):19-22 [9495352.001]
  • [Cites] Pancreas. 1998 Mar;16(2):189-94 [9510143.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4216-23 [9596669.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4387-92 [12560220.001]
  • (PMID = 16937466.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9035-58-9 / Thromboplastin
  • [Other-IDs] NLM/ PMC4087618
  •  go-up   go-down


96. Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC, van Seuningen I, Hollingsworth MA, Aubert JP, Batra SK: MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene; 2007 Jan 4;26(1):30-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms.
  • It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas.
  • In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR.
  • Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases.
  • An aberrant expression of MUC4 was also detected in the CF pancreas.
  • Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology and suggest the implication of new signalling pathway(s) in MUC4 regulation.
  • [MeSH-major] Adenocarcinoma / metabolism. Cystic Fibrosis Transmembrane Conductance Regulator / physiology. Mucins / genetics. Pancreatic Neoplasms / metabolism. Protein Processing, Post-Translational

  • Genetic Alliance. consumer health - BabyFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799633.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 126880-72-6 / Cystic Fibrosis Transmembrane Conductance Regulator
  •  go-up   go-down


97. Qian ZY, Miao Y, Dai CC, Xu ZK, Liu XL: [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct;27(5):572-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas].
  • OBJECTIVE: To investigate the feasibility and therapeutic results of multiple organ resection in patients with tumor of the body and tail of pancreas.
  • METHODS: The clinical and pathological data were analysed in 16 consecutive patients with neoplasm of the body and tail of pancreas from 1999 to 2004 retrospectively.
  • RESULTS: Multiple organ resection was performed in 6 cases of primary pancreatic adenocarcinoma of the body and tail (3 cases of pancreatic cancer, 2 cases of malignant glucagonoma, and 1 case of well-differentiated pancreatic stromal sarcoma) and 10 cases of extrapancreatic malignancy (4 cases of gastric cancer, 2 cases of gastric leiomyosarcoma, 1 case of duodenal cancer, and 3 cases of colon cancer of hepatic flexure).
  • Patients with primary pancreatic cancer or pancreatic stromal sarcoma died within 1 year.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274034.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Hristov B, Reddy S, Lin SH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM: Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys; 2010 Jan 1;76(1):176-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.
  • PURPOSE: Surgery followed by chemotherapy and radiation (CRT) offers patients with pancreatic adenocarcinoma a chance for extended survival.
  • The purpose of this study was to compare outcomes between pancreaticoduodenectomy (PD) with and without mesenterico-portal vein resection (VR) in patients receiving adjuvant CRT for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Mesenteric Veins / surgery. Pancreatic Neoplasms / therapy. Pancreaticoduodenectomy / methods. Portal Vein / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394156.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. de Castro SM, Biere SS, Lagarde SM, Busch OR, van Gulik TM, Gouma DJ: Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg; 2009 Apr;96(4):417-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas.
  • The pancreatic nomogram, originally developed in the Memorial Sloan-Kettering Cancer Center (MSKCC) in the USA, combines clinicopathological and operative data to predict disease-specific survival at 1, 2 and 3 years from initial resection.
  • METHODS: An external patient cohort from a retrospective pancreatic adenocarcinoma database at the Academic Medical Centre in Amsterdam was used to test the validity of the pancreatic adenocarcinoma nomogram.
  • CONCLUSION: The MSKCC pancreatic cancer nomogram provided an accurate survival prediction.
  • [MeSH-major] Adenocarcinoma / surgery. Nomograms. Pancreatic Neoplasms / surgery. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19283741.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


100. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg; 2005 Mar;189(3):278-82
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas.
  • However, the relationship between platelet count and prognosis in pancreatic cancer remains unresolved.
  • METHODS: A chart review of patients undergoing resection for pancreatic adenocarcinoma was undertaken.
  • RESULTS: Between June 1995 and March 2003, 109 patients (63% male) with a median age of 68 years (range 42 to 85 years) underwent resection for pancreatic cancer.
  • CONCLUSIONS: Increased preoperative platelet count is associated with adverse survival outcome in patients undergoing resection for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / mortality. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / mortality. Platelet Count

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792750.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement